UY37676A - Tratamiento para el asma con anticuerpo anti-tslp - Google Patents
Tratamiento para el asma con anticuerpo anti-tslpInfo
- Publication number
- UY37676A UY37676A UY0001037676A UY37676A UY37676A UY 37676 A UY37676 A UY 37676A UY 0001037676 A UY0001037676 A UY 0001037676A UY 37676 A UY37676 A UY 37676A UY 37676 A UY37676 A UY 37676A
- Authority
- UY
- Uruguay
- Prior art keywords
- asthma
- treatment
- tslp antibody
- tslp
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484864P | 2017-04-12 | 2017-04-12 | |
| US201762553575P | 2017-09-01 | 2017-09-01 | |
| US201762553477P | 2017-09-01 | 2017-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37676A true UY37676A (es) | 2018-10-31 |
Family
ID=62092313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037676A UY37676A (es) | 2017-04-12 | 2018-04-12 | Tratamiento para el asma con anticuerpo anti-tslp |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10828365B2 (enExample) |
| EP (1) | EP3609917A1 (enExample) |
| JP (4) | JP7330896B2 (enExample) |
| KR (2) | KR102666879B1 (enExample) |
| CN (1) | CN110573525A (enExample) |
| AU (2) | AU2018253118B2 (enExample) |
| BR (1) | BR112019021482A2 (enExample) |
| CA (1) | CA3059364A1 (enExample) |
| CL (1) | CL2019002897A1 (enExample) |
| CO (1) | CO2019011462A2 (enExample) |
| IL (1) | IL269791B (enExample) |
| JO (1) | JOP20190243B1 (enExample) |
| MX (1) | MX2019012158A (enExample) |
| MY (1) | MY207509A (enExample) |
| PE (1) | PE20200484A1 (enExample) |
| PH (1) | PH12019502331A1 (enExample) |
| SG (1) | SG11201909322VA (enExample) |
| TN (1) | TN2019000289A1 (enExample) |
| TW (2) | TWI856945B (enExample) |
| UA (1) | UA130334C2 (enExample) |
| UY (1) | UY37676A (enExample) |
| WO (1) | WO2018191479A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180042433A (ko) * | 2015-09-09 | 2018-04-25 | 노파르티스 아게 | 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법 |
| JP7330896B2 (ja) * | 2017-04-12 | 2023-08-22 | アムジェン インコーポレイテッド | 抗ｔｓｌｐ抗体による喘息治療 |
| MX2021014804A (es) | 2019-06-04 | 2022-01-18 | Jiangsu Hengrui Medicine Co | Anticuerpo capaz de unirse a la linfopoyetina estromal timica y el uso del mismo. |
| CN114401741A (zh) * | 2019-07-11 | 2022-04-26 | 拓维创新生物科技(香港)有限公司 | 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂 |
| JP7331298B2 (ja) * | 2019-09-04 | 2023-08-23 | ビオシオン インコーポレイテッド | 抗体結合ｔｓｌｐ及びその使用 |
| RS66646B1 (sr) * | 2019-10-28 | 2025-04-30 | Medimmune Ltd | Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe |
| CN114887053B (zh) * | 2019-11-29 | 2026-04-24 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| CA3155759A1 (en) * | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| EP4103605A1 (en) * | 2020-02-13 | 2022-12-21 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| PE20230112A1 (es) * | 2020-02-13 | 2023-01-27 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria |
| PH12022552132A1 (en) * | 2020-02-18 | 2024-01-29 | Amgen Inc | Formulations of human anti-tslp antibodies and methods of using the same |
| CN113388035B (zh) * | 2020-03-13 | 2026-02-27 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| WO2022117079A1 (zh) * | 2020-12-03 | 2022-06-09 | 江苏恒瑞医药股份有限公司 | 结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| IL305230A (en) * | 2021-03-03 | 2023-10-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A pharmaceutical composition containing an anti-TSLP antibody |
| CR20230533A (es) * | 2021-04-19 | 2024-04-05 | Medimmune Ltd | Un fab anti-tslp con estabilidad mejorada |
| AU2022262421A1 (en) | 2021-04-23 | 2023-10-19 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| BR112023022041A2 (pt) | 2021-04-23 | 2023-12-26 | Amgen Inc | Anticorpos anti-tslp modificados |
| CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| CN117327176A (zh) * | 2022-06-24 | 2024-01-02 | 南京融捷康生物科技有限公司 | 一种抗tslp的单域抗体及其用途 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| UY40500A (es) | 2022-10-26 | 2024-04-30 | Amgen Inc | Composiciones de anticuerpos anti-tslp y usos de las mismas |
| AR133648A1 (es) * | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos anti-tslp y sus usos |
| KR20260058856A (ko) | 2023-08-25 | 2026-04-29 | 프로테올로직스 유에스 인크. | 항-il-13 다중특이적 항체 작제물 및 이의 용도 |
| CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
| WO2025179220A1 (en) * | 2024-02-22 | 2025-08-28 | Flagship Pioneering Innovations Vi, Llc | Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp) |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
| WO2026076381A1 (en) * | 2024-10-04 | 2026-04-09 | Prana Therapies, Inc. | Il-4r and tslp inhibitors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| CA2779384C (en) | 2009-11-04 | 2018-02-27 | Schering Corporation | Engineered anti-tslp antibody |
| TW201201840A (en) * | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| BR112016008694A2 (pt) * | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| SG10201913611QA (en) * | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3268032A1 (en) | 2015-03-11 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Tslp binding proteins |
| US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
| JP7330896B2 (ja) * | 2017-04-12 | 2023-08-22 | アムジェン インコーポレイテッド | 抗ｔｓｌｐ抗体による喘息治療 |
-
2018
- 2018-04-12 JP JP2019555854A patent/JP7330896B2/ja active Active
- 2018-04-12 TN TNP/2019/000289A patent/TN2019000289A1/en unknown
- 2018-04-12 UY UY0001037676A patent/UY37676A/es not_active Application Discontinuation
- 2018-04-12 AU AU2018253118A patent/AU2018253118B2/en active Active
- 2018-04-12 EP EP18721605.6A patent/EP3609917A1/en active Pending
- 2018-04-12 SG SG11201909322V patent/SG11201909322VA/en unknown
- 2018-04-12 PE PE2019002026A patent/PE20200484A1/es unknown
- 2018-04-12 CN CN201880026131.3A patent/CN110573525A/zh active Pending
- 2018-04-12 UA UAA201911056A patent/UA130334C2/uk unknown
- 2018-04-12 MY MYPI2019005927A patent/MY207509A/en unknown
- 2018-04-12 MX MX2019012158A patent/MX2019012158A/es unknown
- 2018-04-12 CA CA3059364A patent/CA3059364A1/en active Pending
- 2018-04-12 WO PCT/US2018/027271 patent/WO2018191479A1/en not_active Ceased
- 2018-04-12 TW TW107112622A patent/TWI856945B/zh active
- 2018-04-12 KR KR1020197033043A patent/KR102666879B1/ko active Active
- 2018-04-12 JO JOJO/P/2019/0243A patent/JOP20190243B1/ar active
- 2018-04-12 IL IL269791A patent/IL269791B/en unknown
- 2018-04-12 BR BR112019021482-8A patent/BR112019021482A2/pt unknown
- 2018-04-12 KR KR1020247015858A patent/KR20240070727A/ko active Pending
- 2018-04-12 TW TW113133318A patent/TW202523688A/zh unknown
- 2018-04-12 US US15/951,602 patent/US10828365B2/en active Active
-
2019
- 2019-10-11 CL CL2019002897A patent/CL2019002897A1/es unknown
- 2019-10-11 PH PH12019502331A patent/PH12019502331A1/en unknown
- 2019-10-16 CO CO2019011462A patent/CO2019011462A2/es unknown
-
2020
- 2020-11-09 US US17/093,387 patent/US20210052726A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080295A patent/JP2023099233A/ja not_active Withdrawn
-
2024
- 2024-08-02 JP JP2024127900A patent/JP2024150751A/ja active Pending
- 2024-10-08 US US18/909,660 patent/US20250032608A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204735A patent/AU2025204735A1/en active Pending
- 2025-09-04 JP JP2025147176A patent/JP2025170430A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011462A2 (es) | Tratamiento para el asma con anticuerpo anti-tslp | |
| CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
| ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
| MX387159B (es) | Moléculas basadas en il-15 y métodos para su uso. | |
| CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| BR112017008710A8 (pt) | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva | |
| BR112017023872A2 (pt) | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos | |
| CL2015002357A1 (es) | Nuevos conjugados de anticuerpos y usos de los mismos | |
| CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
| CL2023003432A1 (es) | Fragmento de union fab de igg1 del anticuerpo anti-tslp | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| MX379312B (es) | Anticuerpos especificos para fcrn. | |
| AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
| MX2017012834A (es) | Anticuerpos anti-c1s humanizados y metodos para usarlos. | |
| UY37091A (es) | Cepas fúngicas solubilizantes de fosfato | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| MY202820A (en) | Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof | |
| CL2018003167A1 (es) | Selección de cepas bacterianas útiles en el tratamiento de alergias. | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. | |
| MX393714B (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20241209 |